Journal article icon

Journal article

Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine

Abstract:

Four different vaccine platforms each targeting the human malaria parasite Plasmodium vivax cell- traversal protein for ookinetes and sporozoites (PvCelTOS) were generated and assessed for protective efficacy. These platforms consisted of a recombinant chimpanzee adenoviral vector ChAd63-PvCelTOS (Ad); a recombinant MVA-PvCelTOS (MVA); a bacteriophage Qβ-PvCelTOS virus-like particle (VLP); and recombinant PvCelTOS protein expressed in eukaryotic HEK293T cells (protein). Inbred BALB/c and outb...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1128/CVI.00501-16

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More from this funder
Grant:
FP7/2007-2013) EviMalar 242095
More from this funder
Grant:
097395/Z/11/Z
095540/Z/11/Z
Science Without Borders (Brazil) More from this funder
Publisher:
American Society for Microbiology Publisher's website
Journal:
Clinical and Vaccine Immunology Journal website
Volume:
24
Issue:
4
Pages:
e00501-16
Publication date:
2017-02-08
Acceptance date:
2017-01-31
DOI:
EISSN:
1556-679X
ISSN:
1556-6811
Pubs id:
pubs:675024
UUID:
uuid:194ff738-9e0e-4b3b-91c9-1b7d6dd55403
Local pid:
pubs:675024
Deposit date:
2017-01-31

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP